grant
Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 1 Jul 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025(S)-Malate hydro-lyaseAddressAdvisory CommitteesAffectAggressive Clinical CourseAllelesAllelic LossAllelomorphsAnti-OncogenesAntioncogenesAntioxidantsAppointmentAwardBioinformaticsBiologic ModelsBiological ModelsCancer ModelCancer Suppressor GenesCancer Susceptibility GeneCancer TreatmentCancer-Predisposing GeneCancerModelCancersCell LineCellLineCellular ExpansionCellular GrowthClear cell renal cell carcinomaClinicalClinical geneticsCollaborationsCore FacilityCysteineDNA mutationDevelopmentDevelopment PlansDrug TargetingEarly identificationEmerogenesEnsureFamilyFumaraseFumarase DeficiencyFumarate HydrataseFumarate Hydratase DeficiencyFumaratesFundingFutureGene Expression MonitoringGene Expression Pattern AnalysisGene Expression ProfilingGene ModifiedGenesGeneticGenetic ChangeGenetic PredispositionGenetic Predisposition to DiseaseGenetic ServicesGenetic SusceptibilityGenetic defectGenetic mutationGenetic propensityGenitourinaryGenitourinary systemGenomicsGerm LinesGerm-Line MutationGlutathioneGoalsGrawitz TumorHalf-CystineHereditaryHereditary MutationHereditary Renal Cell CarcinomaHeritabilityHistologicHistologicallyHistologyHuman ResourcesHypernephroid CarcinomaHypernephromaImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodIn VitroIndividualInheritedInherited PredispositionInherited SusceptibilityInstitutionInvestigatorsKidney CancerKidney CarcinomaL-CysteineLaboratoriesLeadLoss of HeterozygosityMSKCCMalignantMalignant - descriptorMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungManpowerMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMedical GeneticsMedicineMemorial Sloan-Kettering Cancer CenterMentorsMentorshipMerlinMetabolicMetabolic PathwayMethodologyModel SystemMoesin-Ezrin-Radixin-Like ProteinMolecularMutateMutationNF2NF2 Gene ProductNF2 geneNephroid CarcinomaNeurofibromatosis 2 Gene ProductNeurofibromatosis 2 GenesNeurofibromatosis Type 2 ProteinNeurofibromin 2Onco-Suppressor GenesOncogenes-Tumor SuppressorsOncogenesisOncogenicOncologyOncology CancerOrganoidsPDX modelPathologicPathway interactionsPatient derived xenograftPatientsPb elementPhenotypePositionPositioning AttributePredispositionPredisposition geneProcessPrognosisPulmonary CancerPulmonary malignant NeoplasmRecessive OncogenesRenal AdenocarcinomaRenal CancerRenal CarcinomaRenal Cell AdenocarcinomaRenal Cell CancerRenal Cell CarcinomaResearchResearch PersonnelResearch ResourcesResearchersResourcesRiskRisk ReductionRoleRunningSchwannomerlinSchwannominSchwannomin ProteinScientistScreening for cancerSomatic MutationStrains Cell LinesSusceptibilitySusceptibility GeneSyndromeTask ForcesTechniquesTestingTrainingTranscript Expression AnalysesTranscript Expression AnalysisTranslational ResearchTranslational ScienceTumor Suppressing GenesTumor Suppressor GenesUnited StatesUpregulationUrogenitalUrogenital SystemVariantVariationWorkadvisory teamanalyze gene expressionanti-cancer therapycancer predispositioncancer preventioncancer therapycancer-directed therapycareer developmentccRCCcell growthcohortcultured cell linedevelopmentalearly cancer detectionexperimentexperimental researchexperimental studyexperimentsfunctional genomicsgamma-L-Glu-L-Cys-Glygamma-L-Glutamyl-L-Cysteinylglycinegene expression analysisgene expression assaygene modificationgenetic epidemiologic studygenetic epidemiologygenetic etiologygenetic mechanism of diseasegenetic vulnerabilitygenetically modifiedgenetically predisposedgenome mutationgenomic profilesgerm-line defectgermline variantheavy metal Pbheavy metal leadimprovedin vivointerestkidney adenocarcinomakidney developmentloss of functionlung cancermalignancymetabolism measurementmetabolomicsmetabonomicsneoplasm/cancernephrogenesisnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnf 2 Genesnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetoncosuppressor genepathwaypatient derived xenograft modelpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespersonnelpredictive toolspredisposing genereduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskresponserisk-reducingscreeningscreening cancer patientsscreeningsskillssocial rolesomatic variantsusceptibility allelesusceptibility locussusceptibility varianttargeted drug therapytargeted drug treatmentstargeted exome sequencingtargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttranscriptional profilingtranscriptomicstranslation researchtranslational investigationtranslational modeltumortumorigenesis
Description preview
PROJECT SUMMARY
Candidate: Maria I. Carlo, MD is an Assistant Attending in Medicine at Memorial Sloan Kettering Cancer
Center (MSK) with a dual appointment in the Genitourinary Oncology and Clinical Genetics services. Dr.
Carlo's clinical and research interests are in hereditary RCC, a cancer that has a poor prognosis when
identified in advanced…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click